Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis

Aiko Ogawa, Katsumasa Miyaji, Ichiro Yamadori, Yoko Shinno, Aya Miura, Kengo F. Kusano, Hiroshi Itoh, Hiroshi Date, Hiromi Matsubara

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare causes of pulmonary hypertension. There is no proven medical therapy to treat these diseases, and lung transplantation is thought to be the only cure. Administration of vasodilators including epoprostenol sometimes causes massive pulmonary edema and could be fatal in these patients. Methods and Results: Eight patients were treated with epoprostenol for 387.3±116.3 days (range, 102-1,063 days), who were finally diagnosed with PVOD or PCH by pathological examination. The maximum dose of epoprostenol given was 55.3±10.7 ng · kg -1 · min -1 (range, 21.0-110.5 ng · kg -1 · min -1). With careful management, epoprostenol therapy significantly improved the 6-min walk distance (97.5±39.2 to 329.4±34.6 m, P-1 · m -2 (P-1 · min -1. Conclusions: This study data suggest that cautious application of epoprostenol can be considered as a therapeutic option in patients with PVOD and PCH.

Original languageEnglish
Pages (from-to)1729-1736
Number of pages8
JournalCirculation Journal
Volume76
Issue number7
DOIs
Publication statusPublished - 2012

Fingerprint

Pulmonary Veno-Occlusive Disease
Epoprostenol
Safety
Lung
Therapeutics
Lung Transplantation
Pulmonary Edema
Vasodilator Agents
Pulmonary Hypertension

Keywords

  • Epoprostenol
  • Pulmonary capillary hemangiomatosis
  • Pulmonary hypertension
  • Pulmonary venoocclusive disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ogawa, A., Miyaji, K., Yamadori, I., Shinno, Y., Miura, A., Kusano, K. F., ... Matsubara, H. (2012). Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circulation Journal, 76(7), 1729-1736. https://doi.org/10.1253/circj.CJ-11-0973

Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. / Ogawa, Aiko; Miyaji, Katsumasa; Yamadori, Ichiro; Shinno, Yoko; Miura, Aya; Kusano, Kengo F.; Itoh, Hiroshi; Date, Hiroshi; Matsubara, Hiromi.

In: Circulation Journal, Vol. 76, No. 7, 2012, p. 1729-1736.

Research output: Contribution to journalArticle

Ogawa, A, Miyaji, K, Yamadori, I, Shinno, Y, Miura, A, Kusano, KF, Itoh, H, Date, H & Matsubara, H 2012, 'Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis', Circulation Journal, vol. 76, no. 7, pp. 1729-1736. https://doi.org/10.1253/circj.CJ-11-0973
Ogawa, Aiko ; Miyaji, Katsumasa ; Yamadori, Ichiro ; Shinno, Yoko ; Miura, Aya ; Kusano, Kengo F. ; Itoh, Hiroshi ; Date, Hiroshi ; Matsubara, Hiromi. / Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. In: Circulation Journal. 2012 ; Vol. 76, No. 7. pp. 1729-1736.
@article{d2f98dcb4d3f429daccffe891d7284a2,
title = "Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis",
abstract = "Background: Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare causes of pulmonary hypertension. There is no proven medical therapy to treat these diseases, and lung transplantation is thought to be the only cure. Administration of vasodilators including epoprostenol sometimes causes massive pulmonary edema and could be fatal in these patients. Methods and Results: Eight patients were treated with epoprostenol for 387.3±116.3 days (range, 102-1,063 days), who were finally diagnosed with PVOD or PCH by pathological examination. The maximum dose of epoprostenol given was 55.3±10.7 ng · kg -1 · min -1 (range, 21.0-110.5 ng · kg -1 · min -1). With careful management, epoprostenol therapy significantly improved the 6-min walk distance (97.5±39.2 to 329.4±34.6 m, P-1 · m -2 (P-1 · min -1. Conclusions: This study data suggest that cautious application of epoprostenol can be considered as a therapeutic option in patients with PVOD and PCH.",
keywords = "Epoprostenol, Pulmonary capillary hemangiomatosis, Pulmonary hypertension, Pulmonary venoocclusive disease",
author = "Aiko Ogawa and Katsumasa Miyaji and Ichiro Yamadori and Yoko Shinno and Aya Miura and Kusano, {Kengo F.} and Hiroshi Itoh and Hiroshi Date and Hiromi Matsubara",
year = "2012",
doi = "10.1253/circj.CJ-11-0973",
language = "English",
volume = "76",
pages = "1729--1736",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "7",

}

TY - JOUR

T1 - Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis

AU - Ogawa, Aiko

AU - Miyaji, Katsumasa

AU - Yamadori, Ichiro

AU - Shinno, Yoko

AU - Miura, Aya

AU - Kusano, Kengo F.

AU - Itoh, Hiroshi

AU - Date, Hiroshi

AU - Matsubara, Hiromi

PY - 2012

Y1 - 2012

N2 - Background: Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare causes of pulmonary hypertension. There is no proven medical therapy to treat these diseases, and lung transplantation is thought to be the only cure. Administration of vasodilators including epoprostenol sometimes causes massive pulmonary edema and could be fatal in these patients. Methods and Results: Eight patients were treated with epoprostenol for 387.3±116.3 days (range, 102-1,063 days), who were finally diagnosed with PVOD or PCH by pathological examination. The maximum dose of epoprostenol given was 55.3±10.7 ng · kg -1 · min -1 (range, 21.0-110.5 ng · kg -1 · min -1). With careful management, epoprostenol therapy significantly improved the 6-min walk distance (97.5±39.2 to 329.4±34.6 m, P-1 · m -2 (P-1 · min -1. Conclusions: This study data suggest that cautious application of epoprostenol can be considered as a therapeutic option in patients with PVOD and PCH.

AB - Background: Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are rare causes of pulmonary hypertension. There is no proven medical therapy to treat these diseases, and lung transplantation is thought to be the only cure. Administration of vasodilators including epoprostenol sometimes causes massive pulmonary edema and could be fatal in these patients. Methods and Results: Eight patients were treated with epoprostenol for 387.3±116.3 days (range, 102-1,063 days), who were finally diagnosed with PVOD or PCH by pathological examination. The maximum dose of epoprostenol given was 55.3±10.7 ng · kg -1 · min -1 (range, 21.0-110.5 ng · kg -1 · min -1). With careful management, epoprostenol therapy significantly improved the 6-min walk distance (97.5±39.2 to 329.4±34.6 m, P-1 · m -2 (P-1 · min -1. Conclusions: This study data suggest that cautious application of epoprostenol can be considered as a therapeutic option in patients with PVOD and PCH.

KW - Epoprostenol

KW - Pulmonary capillary hemangiomatosis

KW - Pulmonary hypertension

KW - Pulmonary venoocclusive disease

UR - http://www.scopus.com/inward/record.url?scp=84863215547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863215547&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-11-0973

DO - 10.1253/circj.CJ-11-0973

M3 - Article

VL - 76

SP - 1729

EP - 1736

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 7

ER -